| Project item | Indications | Research phase | Cooperation demands |
| BNO202202 | Gastric cancer, solid tumor | IND Approval | License-out or co-development |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| MET-R52H9 | Rabbit | Rabbit HGF R / c-MET Protein, His Tag (MALS verified) |  |
|
|
| MET-C52H9 | Cynomolgus | Cynomolgus HGF R / c-MET Protein, His Tag |  |
|
|
| HGR-HF224 | Human | FITC-Labeled Human HGF R / c-MET Protein, His Tag |  |
|
|
| MET-C5256 | Canine | Canine HGF R / c-MET Protein,Fc Tag (MALS verified) |  |
|
|
| MET-R5256 | Rhesus macaque | Rhesus macaque HGF R / c-MET Protein,Fc Tag |  |
|
|
| MET-M5254 | Mouse | Mouse HGF R / c-MET Protein, Fc Tag (MALS verified) |  |
|
|
| MBS-K021 | Human | Human HGF R-coupled Magnetic Beads | |||
| MET-H82E1 | Human | Biotinylated Human HGF R / c-MET Protein, Avitag™,His Tag (MALS verified) |  |
|
|
| MET-H5256 | Human | Human HGF R / c-MET Protein, Fc Tag (MALS verified) |  |
|
|
| MET-H5227 | Human | Human HGF R / c-MET Protein, His Tag |  |
|
|
Immobilized Human HGF, Fc Tag (Cat. No. HGF-H5253) at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human HGF R, His Tag (Cat. No. HGR-HF224) with a linear range of 0.625-10 μg/mL (QC tested).
The purity of Canine HGF R,Fc Tag(Cat. No. MET-C5256) is more than 90% and the molecular weight of this protein is around 290-320 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Amivantamab | JNJ-372; JNJ-61186372 | Approved | Janssen Global Services Llc, Genmab | RYBREVANT | Canada | Carcinoma, Non-Small-Cell Lung | Janssen Inc | 2021-05-21 | Carcinoma, Non-Small-Cell Lung | Details |
| Ensartinib Hydrochloride | X-396 | Approved | Xcovery | 贝美纳 | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2020-11-17 | Solid tumours; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Savolitinib | HM-5016504; AZD-6094; HMP-504; HMPL-504 | Approved | Hutchison Medipharma Ltd | 沃瑞沙, ORPATHYS | Mainland China | Carcinoma, Non-Small-Cell Lung | Hutchison Huangpu Medicine (Shanghai) Co Ltd | 2021-06-22 | Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Capmatinib Hydrochloride | NVP-INC280-NX; INCB-28060; C2A374O70X; INC-280; INCB-028060 | Approved | Novartis Pharma Ag, Incyte Corp | Tabrecta | Japan | Carcinoma, Non-Small-Cell Lung | Novartis Pharma Ag | 2020-05-06 | Liver Neoplasms; Solid tumours; Carcinoma; Adenocarcinoma of Lung; Neoplasms; Triple Negative Breast Neoplasms; Hepatic Insufficiency; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis | Details |
| Tepotinib hydrochloride hydrate | EMD-1214063; MSC-2156119; MSC-2156119J | Approved | Merck Serono | Tepmetko, テプミトコ, TEPMETKO | EU | Carcinoma, Non-Small-Cell Lung | Merck KGaA, Darmstadt, Germany | 2020-03-25 | Solid tumours; Hepatic Insufficiency; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Crizotinib | PF-1066; PF-2341066; PF-02341066; PF-002341066 | Approved | Pfizer Pharmaceuticals Ltd (China) | 赛可瑞, Xalkori | United States | Lymphoma, Large-Cell, Anaplastic | Pf Prism Cv | 2011-08-26 | Colorectal Neoplasms; Neoplasm Metastasis; Neurilemmoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Lung Neoplasms; Ureteral Neoplasms; Solid tumours; Urethral Neoplasms; Neuroblastoma; Uveal melanoma; Urinary Bladder Neoplasms; Myofibroma; Multiple Myeloma; Kidney Diseases; Neurofibromatosis 2; Neoplasms; Hematologic Neoplasms | Details |
| Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Thyroid Neoplasms; Adenocarcinoma, Follicular; Brain Neoplasms; Sarcoma; Neuroblastoma; Neurofibroma, Plexiform; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Bile Duct Neoplasms; Central Nervous System Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Thyroid Cancer, Papillary; Meningioma; Carcinoma, Transitional Cell; Kidney Neoplasms; Ovarian germ cell tumor; Bone metastases; Carcinoma, Renal Cell; Rejection of liver transplantation; Esophageal Neoplasms; Pain; Stomach Neoplasms; Carcinoma, Merkel Cell; Glioblastoma; Seminoma; Solid tumours; Neurofibromatoses; Neoplasms; Salivary Gland Neoplasms; Carcinoma, Papillary; Skin Neoplasms; Kidney Diseases; Neuroendocrine Tumors; Adrenocortical Carcinoma; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SAIT-301 | SAIT-301 | Phase 1 Clinical | Neoplasms | Details | |
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms | Details |
| LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
| Pamufetinib | TAS-115 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd | Neoplasms | Details |
| NP-107 | NP107; NP-107 | Phase 1 Clinical | Shanghai Nawei Biotechnology Co Ltd | Solid tumours | Details |
| Boxitinib Hydrochloride | Phase 1 Clinical | Hec Pharm Co Ltd | Stomach Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Glioma; Lung Neoplasms | Details | |
| CM-118 | CM-118 | Phase 1 Clinical | Xcovery | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AL-2846 | AL-2846 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Advenchen Laboratories Nanjing Ltd | Bone metastases; Liver Neoplasms; Stomach Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Neurofibroma; Neoplasms; Medullary thyroid cancer (MTC); Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neurofibromatosis 1 | Details |
| Bozitinib | PLB-1001; CBT-101; APL-101; CBI-3103 | Phase 2 Clinical | Beijing Purunao Biotechnology Co Ltd, Crown Bioscience, Cbt | Solid tumours; Ganglioglioma; Carcinoma, Non-Small-Cell Lung | Details |
| Emibetuzumab | LA-480; LY-2875358 | Eli Lilly And Company | Details | ||
| GST-HG161 | GST-HG161 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Fujian Cosunter Pharmaceutical Co Ltd | Neoplasms; Carcinoma, Hepatocellular | Details |
| RC-108 | RC-108; RC108 | Phase 1 Clinical | RemeGen Co Ltd | Solid tumours | Details |
| Alirinetide | GM-606; GM-607; GM-608; GM-609; GM-6; GM-600; GM-602; GM-603; GM-604; GM-605 | Genervon Biopharmaceuticals Llc | Details | ||
| LM-061 | LM-061 | Phase 1 Clinical | Shanghai Lixin Pharmaceutical Research and Development Co Ltd | Solid tumours | Details |
| ASKC-202 | ASKC202 | Phase 1 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd | Solid tumours | Details |
| REGN-5093 | REGN-5093 | Regeneron Pharmaceuticals Inc | Details | ||
| HTI-1066 | HTI-1066 | Jiangsu Hengrui Medicine Co Ltd | Details | ||
| SGX-523 | SGX-523 | Eli Lilly And Company | Details | ||
| Elzovantinib | TPX-0022 | Phase 2 Clinical | Turning Point Therapeutics Inc | Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Fosgonimeton | ATH-1017; NDX-1017 | M3 Biotechnology | Details | ||
| Altiratinib | DP-5164; DCC-2701; DCC-22701; T-678746713 | Deciphera | Details | ||
| TR1801-ADC | MT-8633; TR1801-ADC | Tanabe Research Laboratories Usa | Details | ||
| telisotuzumab | Mab224G11; Mabh224G11; h224G11; ABT-700 | Pierre Fabre | Details | ||
| HLX-55 | HLX-55; KTN-0216 | Phase 1 Clinical | Kolltan Pharmaceuticals Inc | Solid tumours | Details |
| Glesatinib | MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly | Mirati Therapeutics | Details | ||
| Refanalin | ANG-3777; BB-3; SNV-003 | Vifor Pharma Ag, Angion Biomedica | Details | ||
| LY-3164530 | LY-3164530 | Eli Lilly And Company | Details | ||
| AMG-208 | AMG-208 | Amgen Inc | Details | ||
| Recombinant plasmid-hepatocyte growth factor | Pudk-HGF | Phase 3 Clinical | Academy Of Military Medical Sciences, Wuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd | Ischemia; Peripheral Arterial Disease | Details |
| REGN-5093-M114 | METxMET-M114; REGN5093-M114 | Regeneron Pharmaceuticals Inc | Details | ||
| ABN-401 | ABN-401; KDDF-201603-08 | Abion Inc | Details | ||
| BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| CBT-101 | CBT-101 | Crown Bioscience | Details | ||
| EMD-1204831 | EMD-1204831 | Merck Serono | Details | ||
| RXDX-106 | RXDX-106 | Teva, Daiichi Sankyo Co Ltd | Details | ||
| PF-04217903 | PF-4217903; PF-04217903; PF-4217903-A | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| JNJ-38877605 | JNJ-38877605 | Johnson & Johnson | Details | ||
| Merestinib | LY-2801653; 5OGS5K699E | Eli Lilly And Company | Details | ||
| c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) | The Second Hospital Of Nanjing Medical University | Details | |||
| MCLA-129 | MCLA-129 | Phase 2 Clinical | Merus | Solid tumours; Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-cMet SIMPLE Antibody | ARGX-111 | Argenx Se | Details | ||
| JNJ-38877618 | OMO-1; JNJ-38877618 | Johnson & Johnson | Details | ||
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 1 Clinical | Hec Pharm Co Ltd | Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
| Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms | Details |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
| Sym-015 | Sym-015 | Phase 2 Clinical | Symphogen | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd | Solid tumours | Details |
| HS-10241 | HS-10241 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Telisotuzumab vedotin | ABT-399; ABBV-399 | Phase 3 Clinical | Abbvie Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| XL-092 | XL-092 | Phase 3 Clinical | Exelixis | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms | Details |
| Sitravatinib | IND-155305; MG-516; MG-91516; MGCD-516 | Phase 3 Clinical | Mirati Therapeutics | Ureteral Neoplasms; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lung Neoplasms; Mouth Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Hepatic Insufficiency; Solid tumours; Breast Neoplasms; Liposarcoma; Lung Diseases; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms | Details |
| CKD-702 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Carcinoma, Non-Small-Cell Lung | Details | |
| SPH3348 | SPH-3348 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Solid tumours; Neoplasms | Details |
| GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
